Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Feasibility
研究概览
简要总结
This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.
All eligible consenting patients will undergo daily stoma management per standard of care.
Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.
Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.
Follow-up: Study participants will be followed at 1 week and 2 weeks.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with osseointegrated prostheses 18 years of age or older
排除标准
- •Ongoing infection
- •Anticipated issues with compliance or follow-up
研究组 & 干预措施
Osseointegration patients
All patients >18 years with osseointegrated prostheses.
干预措施: 5-aminolevulinic acid (5-ALA) (Drug)
Osseointegration patients
All patients >18 years with osseointegrated prostheses.
干预措施: Photodynamic therapy (PDT) (Device)
结局指标
主要结局
Feasibility
时间窗: 2 weeks
Feasibility will be defined as 80% of patients successfully completing the administration protocol as well as 1 week/2-week follow-up.
次要结局
- Discomfort, burning, itchiness, or redness(2 weeks)
- Presence of hypergranulation(2 weeks)
- Pain during light exposure(2 weeks)
- Treatment Evaluation Inventory-Short Form (TEI-SF)(2 weeks)
- System Usability Scale (SUS)(2 weeks)
- Bioburden quantification (16S rRNA sequencing)(2 weeks)
- Bioburden quantification (Optical Coherence Tomography (OCT)(2 weeks)
- OCT "virtual biopsy"(2 weeks)
- Scar thickness(2 weeks)
- Blood vessel density(2 weeks)
研究者
Ida Leah Gitajn
Section Chief, Orthopaedics
Dartmouth-Hitchcock Medical Center
